董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Donald A. Denkhaus | 男 | Director | 77 | 40.33万美元 | 未持股 | 2023-07-12 |
| Molly Harper | 女 | Director | 47 | 39.02万美元 | 未持股 | 2023-07-12 |
| Tamar Thompson | 女 | Director | 49 | 未披露 | 未持股 | 2023-07-12 |
| Patrick J. McEnany | 男 | Chairman,President and CEO | 75 | 692.38万美元 | 未持股 | 2023-07-12 |
| Charles B. O'Keeffe | 男 | Lead Independent Director | 83 | 42.57万美元 | 未持股 | 2023-07-12 |
| David S. Tierney | 男 | Director | 59 | 39.81万美元 | 未持股 | 2023-07-12 |
| Richard J. Daly | 男 | Director | 61 | 39.02万美元 | 未持股 | 2023-07-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gary Ingenito | 男 | Chief Medical and Regulatory Officer | 67 | 248.39万美元 | 未持股 | 2023-07-12 |
| Brian Elsbernd | 男 | Chief Compliance Officer and Chief Legal Officer | 59 | 未披露 | 未持股 | 2023-07-12 |
| Jeffrey Del Carmen | 男 | Chief Commercial Officer | 53 | 238.64万美元 | 未持股 | 2023-07-12 |
| Preethi Sundaram | 女 | Chief Strategy Officer | 48 | 未披露 | 未持股 | 2023-07-12 |
| Patrick J. McEnany | 男 | Chairman,President and CEO | 75 | 692.38万美元 | 未持股 | 2023-07-12 |
| Steven R. Miller | 男 | Chief Operating Officer and Chief Scientific Officer | 61 | 347.48万美元 | 未持股 | 2023-07-12 |
| Alicia Grande | 女 | Vice President, Treasurer and Chief Financial Officer | 52 | 235.40万美元 | 未持股 | 2023-07-12 |
董事简历
中英对照 | 中文 | 英文- Donald A. Denkhaus
-
Donald A. Denkhaus于2015年2月加入公司董事会，现任审计委员会主席。自2005年起开始担任The Kitchen, LLC（一家为电视行业提供语言配音和字幕服务的公司）董事长和首席财务官。从1970年到2002年，身为注册会计师的他在 Arthur Andersen LLP（一家全球专业服务组织）工作，担任22年的审计合伙人，担任多个领导职位，包括 Andersen南佛罗里达审计实践处主管；1998年到2002年担任审计实践合伙人，负责Andersen佛罗里达和波多黎各办事处。从2010年到2013年，Mr. Denkhaus担任Nuovo Biologics（一家私人控股的生物技术公司，正为一项抗病毒药物寻求FDA批准）董事长；2004年到2009年担任Noven Pharmaceuticals，一家公开上市的专业制药公司，主要关注女性的健康和精神病学）董事以及审计委员会主席，该公司于2009年被卖出。Mr. Denkhaus持有the University of Maryland 工商管理硕士学位，主修金融；以及Kent State University工商管理学士学位，主修会计。
Donald A. Denkhaus,joined Catalyst Pharmaceuticals, Inc. Board in February 2015 and currently chairs the Audit Committee of Catalyst Pharmaceuticals, Inc. Board. Since 2005, Mr. Denkhaus has been Chairman and Chief Financial Officer of The Kitchen, LLC, a company providing language dubbing and subtitling services to the media and entertainment industry. From 1970 through 2002, Mr. Denkhaus, who is a retired certified public accountant, worked for Arthur Andersen LLP, a global professional services organization, where he was an audit partner for twenty-two years and held numerous leadership positions, including as head of Andersen's South Florida audit practice and, from 1998 through 2002, as Audit Practice Partner responsible for Andersen's offices in Florida and Puerto Rico. From 2010 to 2013, Mr. Denkhaus was Chair of Nuovo Biologics, a privately held biotech company that was developing an antiviral drug for animal Catalyst Pharmaceuticals, Inc. e, and, from 2004 until its sale in 2009, Mr. Denkhaus served on the board of directors and as chair of the audit committee of Noven Pharmaceuticals, a publicly-traded specialty pharmaceutical company focused on women's health and psychiatry. Mr. Denkhaus received a Master's in Business Administration degree with a major in finance from the University of Maryland and a Bachelor of Business Administration with a major in accounting from Kent State University. - Donald A. Denkhaus于2015年2月加入公司董事会，现任审计委员会主席。自2005年起开始担任The Kitchen, LLC（一家为电视行业提供语言配音和字幕服务的公司）董事长和首席财务官。从1970年到2002年，身为注册会计师的他在 Arthur Andersen LLP（一家全球专业服务组织）工作，担任22年的审计合伙人，担任多个领导职位，包括 Andersen南佛罗里达审计实践处主管；1998年到2002年担任审计实践合伙人，负责Andersen佛罗里达和波多黎各办事处。从2010年到2013年，Mr. Denkhaus担任Nuovo Biologics（一家私人控股的生物技术公司，正为一项抗病毒药物寻求FDA批准）董事长；2004年到2009年担任Noven Pharmaceuticals，一家公开上市的专业制药公司，主要关注女性的健康和精神病学）董事以及审计委员会主席，该公司于2009年被卖出。Mr. Denkhaus持有the University of Maryland 工商管理硕士学位，主修金融；以及Kent State University工商管理学士学位，主修会计。
- Donald A. Denkhaus,joined Catalyst Pharmaceuticals, Inc. Board in February 2015 and currently chairs the Audit Committee of Catalyst Pharmaceuticals, Inc. Board. Since 2005, Mr. Denkhaus has been Chairman and Chief Financial Officer of The Kitchen, LLC, a company providing language dubbing and subtitling services to the media and entertainment industry. From 1970 through 2002, Mr. Denkhaus, who is a retired certified public accountant, worked for Arthur Andersen LLP, a global professional services organization, where he was an audit partner for twenty-two years and held numerous leadership positions, including as head of Andersen's South Florida audit practice and, from 1998 through 2002, as Audit Practice Partner responsible for Andersen's offices in Florida and Puerto Rico. From 2010 to 2013, Mr. Denkhaus was Chair of Nuovo Biologics, a privately held biotech company that was developing an antiviral drug for animal Catalyst Pharmaceuticals, Inc. e, and, from 2004 until its sale in 2009, Mr. Denkhaus served on the board of directors and as chair of the audit committee of Noven Pharmaceuticals, a publicly-traded specialty pharmaceutical company focused on women's health and psychiatry. Mr. Denkhaus received a Master's in Business Administration degree with a major in finance from the University of Maryland and a Bachelor of Business Administration with a major in accounting from Kent State University.
- Molly Harper
-
Molly Harper于2021年6月加入我们的董事会。Harper女士拥有超过20年的经验，专注于各种规模的生命科学公司的战略规划和跨职能领导。自2021年9月起，Harper女士一直担任Synlogic, Inc.的首席商务官，该公司是一家临床阶段的生物制药公司，致力于使用Synlogic的专有药物发现和开发平台发现和开发合成生物药物。在此之前，从2020年5月至2021年9月，哈珀女士担任Relmada治疗公司的运营执行副总裁，该公司是一家后期生物技术公司，致力于解决中枢神经系统疾病。加入Relmada公司之前，她曾担任Akcea Therapeutics公司（开发和商业化公司，专注于罕见疾病）的多种职务，并不断被提拔，在那里她最近担任高级副总裁兼全球特许经营总经理，负责六种药物组合，包括两种已批准的罕见疾病药物。她是Akcea的首批员工之一，她以商业开发副总裁的身份加入该公司。在加入Akcea之前，Harper女士是Sanofi Genzyme罕见病部门的美国内分泌学主管。她曾任职Genzyme公司，包括担任全球和美国营销领导职务，此前曾担任Merck&Co公司的初级保健和医院业务的销售与市场营销职务。在加入Merck之前，Harper女士在UBS Warburg的生命科学股票研究部门工作，并担任威尔克森集团/IBM的战略顾问。Harper女士在康奈尔大学获得文学学士学位，并在宾夕法尼亚大学沃顿商学院获得工商管理硕士学位。Harper女士还担任PrecisedX（一家私人持有的肿瘤AI病理学公司）的董事会成员。
Molly Harper,joined Catalyst Pharmaceuticals, Inc. Board in June 2021. Ms. Harper has over 20 years of experience focusing on strategic planning and cross-functional leadership at life sciences companies of all sizes. Since September 2021, Ms. Harper has been the Chief Business Officer of Synlogic, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of Synthetic Biotics Catalyst Pharmaceuticals, Inc. ing Synlogic's proprietary drug discovery and development platform. Prior thereto, from May 2020 until September 2021, Ms. Harper served as Executive Vice President of Operations for Relmada Therapeutics, Inc., a late-stage biotechnology company addressing diseases of the central nervous system. Prior to joining Relmada, Ms. Harper served in positions of increasing responsibility with Akcea Therapeutics, a development and commercialization company focused on rare diseases, where she was most recently Senior Vice President and Global Franchise General Manager with cross-functional responsibility for a six drug portfolio including two approved rare disease drugs. She was one of the first employees at Akcea, which she joined as VP of Commercial Development. Prior to joining Akcea, Ms. Harper was Head of US Endocrinology in the Rare Disease division of Sanofi Genzyme. Ms. Harper's experience at Genzyme included global and U.S. marketing leadership positions, and she previously held positions across sales and marketing in both primary care and hospital businesses at Merck & Co. Prior to joining Merck, Ms. Harper worked in life sciences equity research at UBS Warburg, and as a strategy consultant with The Wilkerson Group/IBM. Ms. Harper received her Bachelor of Arts from Cornell University and her Master of Business Administration from the Wharton School of the University of Pennsylvania. Ms. Harper also serves on the Board of Directors of PreciseDx, a privately held oncology AI pathology company. - Molly Harper于2021年6月加入我们的董事会。Harper女士拥有超过20年的经验，专注于各种规模的生命科学公司的战略规划和跨职能领导。自2021年9月起，Harper女士一直担任Synlogic, Inc.的首席商务官，该公司是一家临床阶段的生物制药公司，致力于使用Synlogic的专有药物发现和开发平台发现和开发合成生物药物。在此之前，从2020年5月至2021年9月，哈珀女士担任Relmada治疗公司的运营执行副总裁，该公司是一家后期生物技术公司，致力于解决中枢神经系统疾病。加入Relmada公司之前，她曾担任Akcea Therapeutics公司（开发和商业化公司，专注于罕见疾病）的多种职务，并不断被提拔，在那里她最近担任高级副总裁兼全球特许经营总经理，负责六种药物组合，包括两种已批准的罕见疾病药物。她是Akcea的首批员工之一，她以商业开发副总裁的身份加入该公司。在加入Akcea之前，Harper女士是Sanofi Genzyme罕见病部门的美国内分泌学主管。她曾任职Genzyme公司，包括担任全球和美国营销领导职务，此前曾担任Merck&Co公司的初级保健和医院业务的销售与市场营销职务。在加入Merck之前，Harper女士在UBS Warburg的生命科学股票研究部门工作，并担任威尔克森集团/IBM的战略顾问。Harper女士在康奈尔大学获得文学学士学位，并在宾夕法尼亚大学沃顿商学院获得工商管理硕士学位。Harper女士还担任PrecisedX（一家私人持有的肿瘤AI病理学公司）的董事会成员。
- Molly Harper,joined Catalyst Pharmaceuticals, Inc. Board in June 2021. Ms. Harper has over 20 years of experience focusing on strategic planning and cross-functional leadership at life sciences companies of all sizes. Since September 2021, Ms. Harper has been the Chief Business Officer of Synlogic, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of Synthetic Biotics Catalyst Pharmaceuticals, Inc. ing Synlogic's proprietary drug discovery and development platform. Prior thereto, from May 2020 until September 2021, Ms. Harper served as Executive Vice President of Operations for Relmada Therapeutics, Inc., a late-stage biotechnology company addressing diseases of the central nervous system. Prior to joining Relmada, Ms. Harper served in positions of increasing responsibility with Akcea Therapeutics, a development and commercialization company focused on rare diseases, where she was most recently Senior Vice President and Global Franchise General Manager with cross-functional responsibility for a six drug portfolio including two approved rare disease drugs. She was one of the first employees at Akcea, which she joined as VP of Commercial Development. Prior to joining Akcea, Ms. Harper was Head of US Endocrinology in the Rare Disease division of Sanofi Genzyme. Ms. Harper's experience at Genzyme included global and U.S. marketing leadership positions, and she previously held positions across sales and marketing in both primary care and hospital businesses at Merck & Co. Prior to joining Merck, Ms. Harper worked in life sciences equity research at UBS Warburg, and as a strategy consultant with The Wilkerson Group/IBM. Ms. Harper received her Bachelor of Arts from Cornell University and her Master of Business Administration from the Wharton School of the University of Pennsylvania. Ms. Harper also serves on the Board of Directors of PreciseDx, a privately held oncology AI pathology company.
- Tamar Thompson
-
塔玛·汤普森于2023年5月25日加入Catalyst Pharmaceuticals, Inc.董事会。自2021年Alexion被阿斯利康收购以来，汤普森女士一直担任亚力兄制药/阿斯利康罕见病副总裁兼全球企业事务主管。在此之前，汤普森女士于2019年至2021年担任亚力兄制药全球企业事务副总裁。此外，在2015年2月至2019年11月加入Alexion之前，汤普森女士曾在百时美施贵宝公司担任多个职务，最近担任州政府事务和联邦政策执行主任。在加入百时美施贵宝之前，Thompson女士是总部位于华盛顿特区的Premier政府事务公司的战略政策顾问和顾问，包括ADVI、Kimbell and Associates和Avalere Health。最后，自2020年以来，Thompson女士一直担任Avidity Biosciences, Inc.的独立董事，在该公司董事会的提名和治理委员会以及薪酬委员会任职。她还担任MassBio董事会副主席，MassBio是代表马萨诸塞州生物技术行业的首屈一指的州级行业协会。汤普森女士拥有加州赛普拉斯三叉戟大学公共卫生专业的Health Sciences硕士学位。
Tamar Thompson,joined Catalyst Pharmaceuticals, Inc. Board on May 25, 2023. Ms. Thompson has served as Vice President/Head of Global Corporate Affairs for Alexion Pharmaceuticals/AstraZeneca Rare Disease since 2021, when Alexion was acquired by AstraZeneca. Prior thereto, from 2019 to 2021, Ms. Thompson was Vice President, Global Corporate Affairs for Alexion Pharmaceuticals. Further, prior to joining Alexion, from February 2015 to November 2019, when she joined Alexion, Ms. Thompson served in several capacities for Bristol-Myers Squibb Company, most recently as executive director of State Government Affairs and Federal Policy. Prior to joining Bristol-Myers Squibb, Ms. Thompson was a strategic policy advisor and consultant for premiere Washington, DC based governmental affairs firms, including ADVI, Kimbell and Associates and Avalere Health. Finally, since 2020, Ms. Thompson has served as an independent director of Avidity Biosciences, Inc., where she serves on the Nominating and Governance Committee and on the Compensation Committee of that board. She also serves as Vice Chair of the board of directors of MassBio, a premier state level trade association representing the biotech sector in Massachusetts. Ms. Thompson holds an M.S. in Health Sciences with a concentration in Public Health from Trident University in Cypress, California. - 塔玛·汤普森于2023年5月25日加入Catalyst Pharmaceuticals, Inc.董事会。自2021年Alexion被阿斯利康收购以来，汤普森女士一直担任亚力兄制药/阿斯利康罕见病副总裁兼全球企业事务主管。在此之前，汤普森女士于2019年至2021年担任亚力兄制药全球企业事务副总裁。此外，在2015年2月至2019年11月加入Alexion之前，汤普森女士曾在百时美施贵宝公司担任多个职务，最近担任州政府事务和联邦政策执行主任。在加入百时美施贵宝之前，Thompson女士是总部位于华盛顿特区的Premier政府事务公司的战略政策顾问和顾问，包括ADVI、Kimbell and Associates和Avalere Health。最后，自2020年以来，Thompson女士一直担任Avidity Biosciences, Inc.的独立董事，在该公司董事会的提名和治理委员会以及薪酬委员会任职。她还担任MassBio董事会副主席，MassBio是代表马萨诸塞州生物技术行业的首屈一指的州级行业协会。汤普森女士拥有加州赛普拉斯三叉戟大学公共卫生专业的Health Sciences硕士学位。
- Tamar Thompson,joined Catalyst Pharmaceuticals, Inc. Board on May 25, 2023. Ms. Thompson has served as Vice President/Head of Global Corporate Affairs for Alexion Pharmaceuticals/AstraZeneca Rare Disease since 2021, when Alexion was acquired by AstraZeneca. Prior thereto, from 2019 to 2021, Ms. Thompson was Vice President, Global Corporate Affairs for Alexion Pharmaceuticals. Further, prior to joining Alexion, from February 2015 to November 2019, when she joined Alexion, Ms. Thompson served in several capacities for Bristol-Myers Squibb Company, most recently as executive director of State Government Affairs and Federal Policy. Prior to joining Bristol-Myers Squibb, Ms. Thompson was a strategic policy advisor and consultant for premiere Washington, DC based governmental affairs firms, including ADVI, Kimbell and Associates and Avalere Health. Finally, since 2020, Ms. Thompson has served as an independent director of Avidity Biosciences, Inc., where she serves on the Nominating and Governance Committee and on the Compensation Committee of that board. She also serves as Vice Chair of the board of directors of MassBio, a premier state level trade association representing the biotech sector in Massachusetts. Ms. Thompson holds an M.S. in Health Sciences with a concentration in Public Health from Trident University in Cypress, California.
- Patrick J. McEnany
-
Patrick J. McEnany，是Catalyst Pharmaceuticals, Inc.的联合创始人，目前担任Catalyst Pharmaceuticals, Inc.的董事。董事长、总裁兼首席执行官（“首席执行官”）。他曾担任Catalyst Pharmaceuticals, Inc.；自2002年1月Catalyst Pharmaceuticals, Inc.成立以来担任首席执行官和董事。他于2006年3月成为董事长兼总裁。从1999年到2002年，他是制药行业的顾问。从1991年到1997年，他担任Royce Laboratories, Inc.（仿制药制造商）的董事长兼首席执行官。从1997年到1998年，在Royce与Watson Pharmaceuticals, Inc.合并后，他担任全资子公司Royce Laboratories的总裁和Watson Pharmaceuticals, Inc.的企业发展副总裁。从1993年到1997年，他还担任the National Association of Pharmaceutical Manufacturers的副主席兼董事。他目前担任Jackson Health Foundation的名誉董事会成员和the Humane Society of Greater Miami的董事会成员。
Patrick J. McEnany,is a co-founder of Catalyst Pharmaceuticals, Inc. and currently serves as Catalyst Pharmaceuticals, Inc. Chairman, President and Chief Executive Officer ("CEO"). Mr. McEnany has been Catalyst Pharmaceuticals, Inc. CEO and a director since Catalyst Pharmaceuticals, Inc. formation in January 2002. He became Chairman and President in March 2006. From 1999 to 2002, Mr. McEnany was a consultant to the pharmaceutical industry. From 1991 to 1997, Mr. McEnany was Chairman and CEO of Royce Laboratories, Inc., a generic pharmaceutical manufacturer. From 1997 to 1998, after the merger of Royce into Watson Pharmaceuticals, Inc., Mr. McEnany served as president of the wholly-owned Royce Laboratories subsidiary and vice president of corporate development for Watson Pharmaceuticals, Inc. From 1993 to 1997, he also served as vice chairman and a director of the National Association of Pharmaceutical Manufacturers. He currently serves on an emeritus board of directors of the Jackson Health Foundation and on the board of directors of the Humane Society of Greater Miami. - Patrick J. McEnany，是Catalyst Pharmaceuticals, Inc.的联合创始人，目前担任Catalyst Pharmaceuticals, Inc.的董事。董事长、总裁兼首席执行官（“首席执行官”）。他曾担任Catalyst Pharmaceuticals, Inc.；自2002年1月Catalyst Pharmaceuticals, Inc.成立以来担任首席执行官和董事。他于2006年3月成为董事长兼总裁。从1999年到2002年，他是制药行业的顾问。从1991年到1997年，他担任Royce Laboratories, Inc.（仿制药制造商）的董事长兼首席执行官。从1997年到1998年，在Royce与Watson Pharmaceuticals, Inc.合并后，他担任全资子公司Royce Laboratories的总裁和Watson Pharmaceuticals, Inc.的企业发展副总裁。从1993年到1997年，他还担任the National Association of Pharmaceutical Manufacturers的副主席兼董事。他目前担任Jackson Health Foundation的名誉董事会成员和the Humane Society of Greater Miami的董事会成员。
- Patrick J. McEnany,is a co-founder of Catalyst Pharmaceuticals, Inc. and currently serves as Catalyst Pharmaceuticals, Inc. Chairman, President and Chief Executive Officer ("CEO"). Mr. McEnany has been Catalyst Pharmaceuticals, Inc. CEO and a director since Catalyst Pharmaceuticals, Inc. formation in January 2002. He became Chairman and President in March 2006. From 1999 to 2002, Mr. McEnany was a consultant to the pharmaceutical industry. From 1991 to 1997, Mr. McEnany was Chairman and CEO of Royce Laboratories, Inc., a generic pharmaceutical manufacturer. From 1997 to 1998, after the merger of Royce into Watson Pharmaceuticals, Inc., Mr. McEnany served as president of the wholly-owned Royce Laboratories subsidiary and vice president of corporate development for Watson Pharmaceuticals, Inc. From 1993 to 1997, he also served as vice chairman and a director of the National Association of Pharmaceutical Manufacturers. He currently serves on an emeritus board of directors of the Jackson Health Foundation and on the board of directors of the Humane Society of Greater Miami.
- Charles B. O'Keeffe
-
Charles B. O'Keeffe自2004年12月起担任Catalyst Pharmaceuticals，股份有限公司董事会成员，并于2011年7月成为股份有限公司Catalystal Pharmacities的首席独立董事。O'Keepfe先生还于2004年12月份至2011年6月担任Catalist Pharmageuticals，股份有限公司的顾问。O'Keeffe先生是药理学系的教授，弗吉尼亚联邦大学流行病学和社区卫生研究所，自2004年1月1日起担任该职位。O'Keeffe先生在退休后加入弗吉尼亚联邦大学，担任Reckitt Benckiser Pharmaceuticals，Inc.的总裁兼首席执行官。O'Keeffe先生从1991年至2003年担任该职位，担任药物滥用康复服务总裁（1970年至1971年），他开发了第一款抗儿童、抗虐待的美沙酮配药车。1972年至1975年，他担任华盛顿参考实验室主席，该实验室在越南战争期间为国防部提供毒理学服务。他曾在白宫（1970年至1973年，1976年至1980年）担任三任总裁顾问、国际卫生特别助理和药物滥用政策办公室国际事务副主任，并曾在美国出席世界卫生大会和联合国麻醉药品委员会的代表团中任职。
Charles B. O'Keeffe,has served as a member of Catalyst Pharmaceuticals, Inc. Board since December 2004 and became Catalyst Pharmaceuticals, Inc. lead independent director in July 2011. Mr. O'Keeffe also served as a consultant to Catalyst Pharmaceuticals, Inc. from December 2004 until June 2011. Mr. O'Keeffe is a Professor in the Departments of Pharmacology, Epidemiology and Community Health at Virginia Commonwealth University ("VCU") and has served in such capacity since January 1, 2004. Mr. O'Keeffe joined VCU after retiring as President and Chief Executive Officer of Reckitt Benckiser Pharmaceuticals, Inc., a position Mr. O'Keeffe held from 1991 until 2003. As President of Drug Abuse Rehabilitation Services (from 1970 until 1971), he developed the first child-resistant, abuse-resistant vehicle for dispensing methadone. He served as president of Washington Reference Laboratories from 1972 until 1975, which provided toxicology services to the Department of Defense during the Vietnam War. He has served in the White House (from 1970 until 1973 and from 1976 until 1980) for three presidents—as advisor, special assistant for international health and deputy director for international affairs in the Office of Drug Abuse Policy—and has served on U.S. delegations to the World Health Assembly and the U.N. Commission on Narcotic Drugs. - Charles B. O'Keeffe自2004年12月起担任Catalyst Pharmaceuticals，股份有限公司董事会成员，并于2011年7月成为股份有限公司Catalystal Pharmacities的首席独立董事。O'Keepfe先生还于2004年12月份至2011年6月担任Catalist Pharmageuticals，股份有限公司的顾问。O'Keeffe先生是药理学系的教授，弗吉尼亚联邦大学流行病学和社区卫生研究所，自2004年1月1日起担任该职位。O'Keeffe先生在退休后加入弗吉尼亚联邦大学，担任Reckitt Benckiser Pharmaceuticals，Inc.的总裁兼首席执行官。O'Keeffe先生从1991年至2003年担任该职位，担任药物滥用康复服务总裁（1970年至1971年），他开发了第一款抗儿童、抗虐待的美沙酮配药车。1972年至1975年，他担任华盛顿参考实验室主席，该实验室在越南战争期间为国防部提供毒理学服务。他曾在白宫（1970年至1973年，1976年至1980年）担任三任总裁顾问、国际卫生特别助理和药物滥用政策办公室国际事务副主任，并曾在美国出席世界卫生大会和联合国麻醉药品委员会的代表团中任职。
- Charles B. O'Keeffe,has served as a member of Catalyst Pharmaceuticals, Inc. Board since December 2004 and became Catalyst Pharmaceuticals, Inc. lead independent director in July 2011. Mr. O'Keeffe also served as a consultant to Catalyst Pharmaceuticals, Inc. from December 2004 until June 2011. Mr. O'Keeffe is a Professor in the Departments of Pharmacology, Epidemiology and Community Health at Virginia Commonwealth University ("VCU") and has served in such capacity since January 1, 2004. Mr. O'Keeffe joined VCU after retiring as President and Chief Executive Officer of Reckitt Benckiser Pharmaceuticals, Inc., a position Mr. O'Keeffe held from 1991 until 2003. As President of Drug Abuse Rehabilitation Services (from 1970 until 1971), he developed the first child-resistant, abuse-resistant vehicle for dispensing methadone. He served as president of Washington Reference Laboratories from 1972 until 1975, which provided toxicology services to the Department of Defense during the Vietnam War. He has served in the White House (from 1970 until 1973 and from 1976 until 1980) for three presidents—as advisor, special assistant for international health and deputy director for international affairs in the Office of Drug Abuse Policy—and has served on U.S. delegations to the World Health Assembly and the U.N. Commission on Narcotic Drugs.
- David S. Tierney
-
David S. Tierney，自2015年3月起担任Zevra Therapeutics公司董事。自2020年12月起，Tierney博士担任临床阶段免疫眼科生物制药公司Aramis Biosciences的总裁兼首席执行官。从2020年2月到2020年12月，Tierney博士担任Pharma Two B，Ltd.的首席执行官，这是一家私有公司，开发基于先前批准的帕金森病药物的创新疗法。从2019年9月到2020年1月，Tierney博士担任皮肤病药物开发公司BiopharmX的总裁兼首席执行官。2014年3月至2018年3月，Tierney博士担任私人控股的眼科公司Icon Bioscience，Inc.的总裁兼首席执行官，Icon Bioscience，Inc.并入Psivida，Inc，成立Eyepoint Pharmaceuticals。从2013年1月到2014年3月，Tierney博士是总部位于纽约的生命科学私人股本基金Signet Healthcare Partners的风险合伙人。Tierney博士曾担任Oceana Therapeutics，Inc.的总裁兼首席运营官和董事会成员。Oceana Therapeutics，Inc.是一家私营专业制药公司，从2008年成立到2011年12月将其出售给Salix Pharmaceuticals，Ltd.。Tierney博士曾在2000年8月至2007年4月期间担任Valera Pharmaceuticals，Inc.的总裁兼首席执行官和董事会成员，Valera是一家专业制药公司，Valera完成了与lndevus Pharmaceuticals，Inc.的合并。从2000年1月至2000年8月，Tierney博士担任加拿大药物递送公司Biovail Corporation的子公司Biovail Technologies的总裁。1997年3月至2000年1月，Tierney在罗伯茨制药公司担任药物开发高级副总裁，1989年12月至1997年3月，蒂尔尼博士受雇于制药公司Elan公司，担任各种管理职务。Tierney博士目前还担任催化剂制药公司董事，并曾于2019年至2020年担任BioPharmX公司董事。Tierney博士在爱尔兰都柏林的皇家外科医学院获得医学学位，随后接受了内科培训。
David S. Tierney,has served as a member of Catalyst Pharmaceuticals, Inc. Board since October 2002 and currently chairs the Compensation Committee of Catalyst Pharmaceuticals, Inc. Board. Dr. Tierney currently serves as Chief Executive Officer and Director of Aramis Biosciences, a privately held clinical stage ophthalmology pharmaceutical company. From February 2020 until December 2020, Dr. Tierney served as CEO of Pharma Two B, a CNS specialty pharmaceutical company. From September 2018 until January 2020, Dr. Tierney served as President & CEO of BioPharmX Corporation, a dermatology specialty pharmaceutical company. He also served on the Board of Directors of BioPharmX from September 2018 until May 2020. From January 2014 until March 2018, he served as President & CEO of Icon Bioscience, Inc., a privately held ophthalmic drug delivery company. Dr. Tierney served as President and Chief Operating Officer (and a member of the board of directors) of Oceana Therapeutics, Inc., a private specialty pharmaceutical company between the organization of that company in 2008 and the sale of that company to Salix Pharmaceuticals, Ltd. in December 2011. Dr. Tierney also served as the President and CEO (and as a member of the board of directors) of Valera Pharmaceuticals, Inc. a specialty pharmaceutical company, between August 2000 and April 2007, when Valera completed a merger with Indevus Pharmaceuticals, Inc. Further, from January 2000 to August 2000, Dr. Tierney served as President of Biovail Technologies, a division of Biovail Corporation, a Canadian drug delivery company, where he was responsible for all of Biovail's research and development, regulatory and clinical activities. Finally, from March 1997 to January 2000, Dr. Tierney was Senior Vice President of Drug Development at Roberts Pharmaceutical Corporation, where he was responsible for all research and development activities, and for drug development, medical affairs, worldwide regulatory affairs and chemical process development, as well as being part of the executive management team, and from December 1989 to March 1997, Dr. Tierney was employed by lan Corporation, a pharmaceutical company, in a variety of management positions. Dr. Tierney was until recently a director of Kempharm, Inc. (n/k/a Zevra Therapeutics) and is currently a director of Bimeda, Inc. Dr. Tierney received his medical degree from the Royal College of Surgeons in Dublin, Ireland and was subsequently trained in internal medicine. - David S. Tierney，自2015年3月起担任Zevra Therapeutics公司董事。自2020年12月起，Tierney博士担任临床阶段免疫眼科生物制药公司Aramis Biosciences的总裁兼首席执行官。从2020年2月到2020年12月，Tierney博士担任Pharma Two B，Ltd.的首席执行官，这是一家私有公司，开发基于先前批准的帕金森病药物的创新疗法。从2019年9月到2020年1月，Tierney博士担任皮肤病药物开发公司BiopharmX的总裁兼首席执行官。2014年3月至2018年3月，Tierney博士担任私人控股的眼科公司Icon Bioscience，Inc.的总裁兼首席执行官，Icon Bioscience，Inc.并入Psivida，Inc，成立Eyepoint Pharmaceuticals。从2013年1月到2014年3月，Tierney博士是总部位于纽约的生命科学私人股本基金Signet Healthcare Partners的风险合伙人。Tierney博士曾担任Oceana Therapeutics，Inc.的总裁兼首席运营官和董事会成员。Oceana Therapeutics，Inc.是一家私营专业制药公司，从2008年成立到2011年12月将其出售给Salix Pharmaceuticals，Ltd.。Tierney博士曾在2000年8月至2007年4月期间担任Valera Pharmaceuticals，Inc.的总裁兼首席执行官和董事会成员，Valera是一家专业制药公司，Valera完成了与lndevus Pharmaceuticals，Inc.的合并。从2000年1月至2000年8月，Tierney博士担任加拿大药物递送公司Biovail Corporation的子公司Biovail Technologies的总裁。1997年3月至2000年1月，Tierney在罗伯茨制药公司担任药物开发高级副总裁，1989年12月至1997年3月，蒂尔尼博士受雇于制药公司Elan公司，担任各种管理职务。Tierney博士目前还担任催化剂制药公司董事，并曾于2019年至2020年担任BioPharmX公司董事。Tierney博士在爱尔兰都柏林的皇家外科医学院获得医学学位，随后接受了内科培训。
- David S. Tierney,has served as a member of Catalyst Pharmaceuticals, Inc. Board since October 2002 and currently chairs the Compensation Committee of Catalyst Pharmaceuticals, Inc. Board. Dr. Tierney currently serves as Chief Executive Officer and Director of Aramis Biosciences, a privately held clinical stage ophthalmology pharmaceutical company. From February 2020 until December 2020, Dr. Tierney served as CEO of Pharma Two B, a CNS specialty pharmaceutical company. From September 2018 until January 2020, Dr. Tierney served as President & CEO of BioPharmX Corporation, a dermatology specialty pharmaceutical company. He also served on the Board of Directors of BioPharmX from September 2018 until May 2020. From January 2014 until March 2018, he served as President & CEO of Icon Bioscience, Inc., a privately held ophthalmic drug delivery company. Dr. Tierney served as President and Chief Operating Officer (and a member of the board of directors) of Oceana Therapeutics, Inc., a private specialty pharmaceutical company between the organization of that company in 2008 and the sale of that company to Salix Pharmaceuticals, Ltd. in December 2011. Dr. Tierney also served as the President and CEO (and as a member of the board of directors) of Valera Pharmaceuticals, Inc. a specialty pharmaceutical company, between August 2000 and April 2007, when Valera completed a merger with Indevus Pharmaceuticals, Inc. Further, from January 2000 to August 2000, Dr. Tierney served as President of Biovail Technologies, a division of Biovail Corporation, a Canadian drug delivery company, where he was responsible for all of Biovail's research and development, regulatory and clinical activities. Finally, from March 1997 to January 2000, Dr. Tierney was Senior Vice President of Drug Development at Roberts Pharmaceutical Corporation, where he was responsible for all research and development activities, and for drug development, medical affairs, worldwide regulatory affairs and chemical process development, as well as being part of the executive management team, and from December 1989 to March 1997, Dr. Tierney was employed by lan Corporation, a pharmaceutical company, in a variety of management positions. Dr. Tierney was until recently a director of Kempharm, Inc. (n/k/a Zevra Therapeutics) and is currently a director of Bimeda, Inc. Dr. Tierney received his medical degree from the Royal College of Surgeons in Dublin, Ireland and was subsequently trained in internal medicine.
- Richard J. Daly
-
Richard J. Daly，加入Catalyst Pharmaceuticals, Inc.。2015年2月加入董事会。Daly先生目前担任CARsgen Therapeutics公司（一家新兴的肿瘤学公司，专注于开发用于液体和实体肿瘤的CAR-T疗法）的总裁。从2018年7月到2022年1月，Daly先生担任BeyondSpring Pharmaceuticals的首席运营官，这是一家商业化前的生物技术公司，专注于肿瘤学，资产处于后期3期临床试验。在2018年8月加入BeyondSpring之前，（i） 2016年2月至2018年7月，Daly先生担任Neuralstem, Inc.（一家专注于基于其神经干细胞技术开发中枢神经系统疗法的生物制药公司）的董事长兼首席执行官，（ii） 2014年10月至2016年9月，Daly先生担任RavineRock Partners的合伙人，RavineRock Partners是一家专注于生物技术和制药的商业咨询公司，以及（iii） 2013年2月至2014年9月。Daly先生曾担任AstraZeneca US Diabetes总裁。从2018年到2023年该公司被出售，Daly先生担任Opiant Pharmaceuticals的董事会成员，并担任董事会薪酬和审计委员会成员。从2015年6月到2018年6月，Daly先生还担任Synergy Pharmaceuticals的董事会成员，在那里他担任提名/公司治理委员会主席，并担任薪酬委员会成员。他于1983年获得the University of Notre Dame的微生物学学士学位，并于1998年获得the Kellogg School of Management, Northwestern University的工商管理硕士学位。
Richard J. Daly,joined Catalyst Pharmaceuticals, Inc. Board in February 2015. Mr. Daly currently serves as President of CARsgen Therapeutics Corporation, an emerging oncology company focused on developing CAR-T therapies for both liquid and solid tumors. From July 2018 through January 2022, Mr. Daly served as Chief Operating Officer of BeyondSpring Pharmaceuticals, a pre-commercial biotech company focused on oncology with assets in late Phase 3 clinical trials. Before joining BeyondSpring in August 2018, (i) from February 2016 to July 218 Mr. Daly served as Chairman and CEO of Neuralstem, Inc., a biopharmaceutical company focused on the development of central nervous system therapies based on its neuronal stem cell technology, (ii) from October 2014 to September 2016, Mr. Daly served as a partner of RavineRock Partners, a commercial consulting practice focused on biotech and pharmaceuticals, and (iii) from February 2013 to September 2014, Mr. Daly served as President of AstraZeneca US Diabetes. Mr. Daly served on the board of directors of Opiant Pharmaceuticals, and as a member of that board's Compensation and Audit Committees, from 2018 until the sale of that company in 2023. From June 2015 to June 2018 Mr. Daly also served on the Board of Directors of Synergy Pharmaceuticals, where he chaired the Nominations/Corporate Governance Committee and was a member of the Compensation Committee. Mr. Daly received his Bachelor of Science in Microbiology from the University of Notre Dame in 1983 and his MBA from the Kellogg School of Management, Northwestern University in 1998. - Richard J. Daly，加入Catalyst Pharmaceuticals, Inc.。2015年2月加入董事会。Daly先生目前担任CARsgen Therapeutics公司（一家新兴的肿瘤学公司，专注于开发用于液体和实体肿瘤的CAR-T疗法）的总裁。从2018年7月到2022年1月，Daly先生担任BeyondSpring Pharmaceuticals的首席运营官，这是一家商业化前的生物技术公司，专注于肿瘤学，资产处于后期3期临床试验。在2018年8月加入BeyondSpring之前，（i） 2016年2月至2018年7月，Daly先生担任Neuralstem, Inc.（一家专注于基于其神经干细胞技术开发中枢神经系统疗法的生物制药公司）的董事长兼首席执行官，（ii） 2014年10月至2016年9月，Daly先生担任RavineRock Partners的合伙人，RavineRock Partners是一家专注于生物技术和制药的商业咨询公司，以及（iii） 2013年2月至2014年9月。Daly先生曾担任AstraZeneca US Diabetes总裁。从2018年到2023年该公司被出售，Daly先生担任Opiant Pharmaceuticals的董事会成员，并担任董事会薪酬和审计委员会成员。从2015年6月到2018年6月，Daly先生还担任Synergy Pharmaceuticals的董事会成员，在那里他担任提名/公司治理委员会主席，并担任薪酬委员会成员。他于1983年获得the University of Notre Dame的微生物学学士学位，并于1998年获得the Kellogg School of Management, Northwestern University的工商管理硕士学位。
- Richard J. Daly,joined Catalyst Pharmaceuticals, Inc. Board in February 2015. Mr. Daly currently serves as President of CARsgen Therapeutics Corporation, an emerging oncology company focused on developing CAR-T therapies for both liquid and solid tumors. From July 2018 through January 2022, Mr. Daly served as Chief Operating Officer of BeyondSpring Pharmaceuticals, a pre-commercial biotech company focused on oncology with assets in late Phase 3 clinical trials. Before joining BeyondSpring in August 2018, (i) from February 2016 to July 218 Mr. Daly served as Chairman and CEO of Neuralstem, Inc., a biopharmaceutical company focused on the development of central nervous system therapies based on its neuronal stem cell technology, (ii) from October 2014 to September 2016, Mr. Daly served as a partner of RavineRock Partners, a commercial consulting practice focused on biotech and pharmaceuticals, and (iii) from February 2013 to September 2014, Mr. Daly served as President of AstraZeneca US Diabetes. Mr. Daly served on the board of directors of Opiant Pharmaceuticals, and as a member of that board's Compensation and Audit Committees, from 2018 until the sale of that company in 2023. From June 2015 to June 2018 Mr. Daly also served on the Board of Directors of Synergy Pharmaceuticals, where he chaired the Nominations/Corporate Governance Committee and was a member of the Compensation Committee. Mr. Daly received his Bachelor of Science in Microbiology from the University of Notre Dame in 1983 and his MBA from the Kellogg School of Management, Northwestern University in 1998.
高管简历
中英对照 | 中文 | 英文- Gary Ingenito
Gary Ingenito，现任Catalyst Pharmaceuticals, Inc.首席医疗和监管官。他于2015年6月加入Catalyst Pharmaceuticals, Inc.，担任Catalyst Pharmaceuticals, Inc.首席医疗官，并于2016年2月接管Catalyst Pharmaceuticals, Inc.的监管业务。在加入Catalyst之前，Ingenito博士在制药开发领域工作了超过25年，包括药物、生物制剂和组合产品。在此期间，Ingenito博士在制药公司和合同研究机构担任临床研究、监管、药物安全和医疗事务的执行职责。Ingenito博士最初加入Sandoz Pharmaceuticals的神经内分泌组，并晋升为医疗事务主管。他在大冢制药公司工作了8年，负责监督抗感染、心血管和中枢神经系统产品的批准。他在Otsuka Pharmaceuticals工作了8年，负责监督抗感染、心血管和中枢神经系统产品的批准。他还曾在Corning-Besselaar、SFBC International、Angiotech Pharmaceuticals、Biotest Pharmaceuticals担任职务，最近在Boehringer-Ingelheim Pharmaceuticals担任生物仿制药北美监管事务主管。在获得The Johns Hopkins University的文学学士学位后，Ingenito博士在Jefferson medical College获得医学学位，并在Thomas Jefferson University获得哲学博士学位。他在University of Miami, Jackson Memorial Hospital完成了神经病学的研究生实习。
Gary Ingenito,is Catalyst Pharmaceuticals, Inc. Chief Medical and Regulatory Officer. He joined Catalyst Pharmaceuticals, Inc. as Catalyst Pharmaceuticals, Inc. Chief Medical Officer in June 2015 and took over Catalyst Pharmaceuticals, Inc. regulatory operations in February 2016. Prior to joining Catalyst, Dr. Ingenito spent more than 25 years in the field of pharmaceutical development; including drugs, biologics, and combination products. During this time, Dr. Ingenito has held executive responsibilities for clinical research, regulatory, drug safety, and medical affairs at pharmaceutical companies and contract research organizations. Dr. Ingenito initially joined Sandoz Pharmaceuticals in the neuroendocrine group and progressed to become head of medical affairs. He spent 8 years at Otsuka Pharmaceuticals, overseeing the approval of anti-infective, cardiovascular, and central nervous system products. Dr. Ingenito has also held positions at Corning-Besselaar, SFBC International, Angiotech Pharmaceuticals, Biotest Pharmaceuticals, and, most recently at Boehringer-Ingelheim Pharmaceuticals, where he served as head of regulatory affairs North America for biosimilars. After obtaining his Bachelor of Arts degree from The Johns Hopkins University, Dr. Ingenito earned his medical degree at Jefferson Medical College, and a Ph.D. in philosophy from Thomas Jefferson University. He completed a post-graduate residency in neurology at the University of Miami, Jackson Memorial Hospital.- Gary Ingenito，现任Catalyst Pharmaceuticals, Inc.首席医疗和监管官。他于2015年6月加入Catalyst Pharmaceuticals, Inc.，担任Catalyst Pharmaceuticals, Inc.首席医疗官，并于2016年2月接管Catalyst Pharmaceuticals, Inc.的监管业务。在加入Catalyst之前，Ingenito博士在制药开发领域工作了超过25年，包括药物、生物制剂和组合产品。在此期间，Ingenito博士在制药公司和合同研究机构担任临床研究、监管、药物安全和医疗事务的执行职责。Ingenito博士最初加入Sandoz Pharmaceuticals的神经内分泌组，并晋升为医疗事务主管。他在大冢制药公司工作了8年，负责监督抗感染、心血管和中枢神经系统产品的批准。他在Otsuka Pharmaceuticals工作了8年，负责监督抗感染、心血管和中枢神经系统产品的批准。他还曾在Corning-Besselaar、SFBC International、Angiotech Pharmaceuticals、Biotest Pharmaceuticals担任职务，最近在Boehringer-Ingelheim Pharmaceuticals担任生物仿制药北美监管事务主管。在获得The Johns Hopkins University的文学学士学位后，Ingenito博士在Jefferson medical College获得医学学位，并在Thomas Jefferson University获得哲学博士学位。他在University of Miami, Jackson Memorial Hospital完成了神经病学的研究生实习。
- Gary Ingenito,is Catalyst Pharmaceuticals, Inc. Chief Medical and Regulatory Officer. He joined Catalyst Pharmaceuticals, Inc. as Catalyst Pharmaceuticals, Inc. Chief Medical Officer in June 2015 and took over Catalyst Pharmaceuticals, Inc. regulatory operations in February 2016. Prior to joining Catalyst, Dr. Ingenito spent more than 25 years in the field of pharmaceutical development; including drugs, biologics, and combination products. During this time, Dr. Ingenito has held executive responsibilities for clinical research, regulatory, drug safety, and medical affairs at pharmaceutical companies and contract research organizations. Dr. Ingenito initially joined Sandoz Pharmaceuticals in the neuroendocrine group and progressed to become head of medical affairs. He spent 8 years at Otsuka Pharmaceuticals, overseeing the approval of anti-infective, cardiovascular, and central nervous system products. Dr. Ingenito has also held positions at Corning-Besselaar, SFBC International, Angiotech Pharmaceuticals, Biotest Pharmaceuticals, and, most recently at Boehringer-Ingelheim Pharmaceuticals, where he served as head of regulatory affairs North America for biosimilars. After obtaining his Bachelor of Arts degree from The Johns Hopkins University, Dr. Ingenito earned his medical degree at Jefferson Medical College, and a Ph.D. in philosophy from Thomas Jefferson University. He completed a post-graduate residency in neurology at the University of Miami, Jackson Memorial Hospital.
- Brian Elsbernd
Brian Elsbernd，于2016年2月加入Catalyst Pharmaceuticals, Inc.，担任Catalyst Pharmaceuticals, Inc.。法律和合规高级副总裁，并成为Catalyst Pharmaceuticals, Inc.。自2019年1月1日起担任首席合规官和首席法律官。加入Catalyst之前，从2004年到2016年2月，他曾在Mallinckrodt Pharmaceuticals及其前身公司担任各种职务，包括担任美国医疗保健合规高级总监。在Mallinckrodt，他参与了正式合规计划的建立，包括在道德和商业行为方面提供领导和愿景，同时还管理多个其他法律和业务职能。在加入Mallinckrodt之前，他是Proskauer Rose LLP的助理，在其医疗保健实践小组内，代表全国的医疗保健提供者处理与监管和行政法、交易事项、诉讼和报销问题有关的事务。他持有the University of Illinois-Urbana的历史文学学士学位和the Saint Louis University School of law的法律学位。
Brian Elsbernd,joined Catalyst Pharmaceuticals, Inc. in February 2016 as Catalyst Pharmaceuticals, Inc. Sr. Vice President of Legal and Compliance and became Catalyst Pharmaceuticals, Inc. Chief Compliance Officer and Chief Legal Officer on January 1, 2019. Prior to joining Catalyst, Mr. Elsbernd was, from 2004 until February 2016, employed in various capacities with Mallinckrodt Pharmaceuticals and its predecessors, including as Senior Director of U.S. Healthcare Compliance. At Mallinckrodt, he was involved in the building of their formal compliance program including providing leadership and vision on ethics and business conduct while also managing multiple other legal and business functions. Before joining Mallinckrodt, Mr. Elsbernd was an associate at Proskauer Rose LLP, within its Health Care practice group, representing health care providers nationwide in matters pertaining to regulatory and administrative law, transactional matters, litigation, and reimbursement issues. Mr. Elsbernd holds a Bachelor of Arts degree in history from the University of Illinois-Urbana and a law degree from the Saint Louis University School of Law.- Brian Elsbernd，于2016年2月加入Catalyst Pharmaceuticals, Inc.，担任Catalyst Pharmaceuticals, Inc.。法律和合规高级副总裁，并成为Catalyst Pharmaceuticals, Inc.。自2019年1月1日起担任首席合规官和首席法律官。加入Catalyst之前，从2004年到2016年2月，他曾在Mallinckrodt Pharmaceuticals及其前身公司担任各种职务，包括担任美国医疗保健合规高级总监。在Mallinckrodt，他参与了正式合规计划的建立，包括在道德和商业行为方面提供领导和愿景，同时还管理多个其他法律和业务职能。在加入Mallinckrodt之前，他是Proskauer Rose LLP的助理，在其医疗保健实践小组内，代表全国的医疗保健提供者处理与监管和行政法、交易事项、诉讼和报销问题有关的事务。他持有the University of Illinois-Urbana的历史文学学士学位和the Saint Louis University School of law的法律学位。
- Brian Elsbernd,joined Catalyst Pharmaceuticals, Inc. in February 2016 as Catalyst Pharmaceuticals, Inc. Sr. Vice President of Legal and Compliance and became Catalyst Pharmaceuticals, Inc. Chief Compliance Officer and Chief Legal Officer on January 1, 2019. Prior to joining Catalyst, Mr. Elsbernd was, from 2004 until February 2016, employed in various capacities with Mallinckrodt Pharmaceuticals and its predecessors, including as Senior Director of U.S. Healthcare Compliance. At Mallinckrodt, he was involved in the building of their formal compliance program including providing leadership and vision on ethics and business conduct while also managing multiple other legal and business functions. Before joining Mallinckrodt, Mr. Elsbernd was an associate at Proskauer Rose LLP, within its Health Care practice group, representing health care providers nationwide in matters pertaining to regulatory and administrative law, transactional matters, litigation, and reimbursement issues. Mr. Elsbernd holds a Bachelor of Arts degree in history from the University of Illinois-Urbana and a law degree from the Saint Louis University School of Law.
- Jeffrey Del Carmen
Jeffrey del Carmen自2020年6月23日起担任我们的首席商务官。此前，Del Carmen先生自2018年7月起担任我们的销售与市场营销高级副总裁。Del Carmen先生在药品销售和项目管理方面有着超过25年的经验。在加入Catalyst之前，Del Carmen先生于2018年1月至2018年7月担任Paragon Biosciences业务发展Vice President，负责评估商业资产以扩大Paragon的投资组合。从2016年9月到2017年6月被PTC Therapeutics收购，Del Carmen先生担任Marathon Pharmaceuticals罕见病营销高级总监，领导Marathon为Emflaza商业化所做的营销工作。2016年1月至2016年8月，Del Carmen先生担任Insys Therapeutics的销售Vice President。2011年8月至2016年1月，Del Carmen先生受聘于Lundbeck Inc.，在Lundbeck任职的最后两年，他担任Movement Disorder全国销售总监。在加入Lundbeck之前，Del Carmen先生在雅培公司工作了16年，担任过各种销售与市场营销领导职务，责任越来越大。Del Carmen先生拥有University of Dayton经济学文学学士学位和University of Wisconsin执行工商管理硕士学位。
Jeffrey Del Carmen,has been Catalyst Pharmaceuticals, Inc. Chief Commercial Officer since June 23, 2020. Previously, since July 2018, Mr. Del Carmen served as Catalyst Pharmaceuticals, Inc. Senior Vice President of Sales and Marketing. Mr. Del Carmen has over 25 years of experience in pharmaceutical sales and project management. Prior to joining Catalyst, from January 2018 until July 2018, Mr. Del Carmen served as Vice President of Business Development of Paragon Biosciences evaluating commercial assets to expand Paragon's portfolio. From September 2016 until June 2017 (when it was acquired by PTC Therapeutics), Mr. Del Carmen was Senior Director, Rare Disease Marketing for Marathon Pharmaceuticals, leading Marathon's marketing efforts for the commercialization of Emflaza. From January 2016 to August 2016, Mr. Del Carmen served as Vice President of Sales at Insys Therapeutics. From August 2011 until January 2016, Mr. Del Carmen was employed by Lundbeck Inc., where for the last two years of his tenure at Lundbeck he was the Movement Disorder National Sales Director. Prior to joining Lundbeck, Mr. Del Carmen spent 16 years at Abbott Laboratories in various sales and marketing leadership roles, with increasing responsibility. Mr. Del Carmen holds a Bachelor of Arts degree in Economics from the University of Dayton and an Executive MBA Degree from the University of Wisconsin.- Jeffrey del Carmen自2020年6月23日起担任我们的首席商务官。此前，Del Carmen先生自2018年7月起担任我们的销售与市场营销高级副总裁。Del Carmen先生在药品销售和项目管理方面有着超过25年的经验。在加入Catalyst之前，Del Carmen先生于2018年1月至2018年7月担任Paragon Biosciences业务发展Vice President，负责评估商业资产以扩大Paragon的投资组合。从2016年9月到2017年6月被PTC Therapeutics收购，Del Carmen先生担任Marathon Pharmaceuticals罕见病营销高级总监，领导Marathon为Emflaza商业化所做的营销工作。2016年1月至2016年8月，Del Carmen先生担任Insys Therapeutics的销售Vice President。2011年8月至2016年1月，Del Carmen先生受聘于Lundbeck Inc.，在Lundbeck任职的最后两年，他担任Movement Disorder全国销售总监。在加入Lundbeck之前，Del Carmen先生在雅培公司工作了16年，担任过各种销售与市场营销领导职务，责任越来越大。Del Carmen先生拥有University of Dayton经济学文学学士学位和University of Wisconsin执行工商管理硕士学位。
- Jeffrey Del Carmen,has been Catalyst Pharmaceuticals, Inc. Chief Commercial Officer since June 23, 2020. Previously, since July 2018, Mr. Del Carmen served as Catalyst Pharmaceuticals, Inc. Senior Vice President of Sales and Marketing. Mr. Del Carmen has over 25 years of experience in pharmaceutical sales and project management. Prior to joining Catalyst, from January 2018 until July 2018, Mr. Del Carmen served as Vice President of Business Development of Paragon Biosciences evaluating commercial assets to expand Paragon's portfolio. From September 2016 until June 2017 (when it was acquired by PTC Therapeutics), Mr. Del Carmen was Senior Director, Rare Disease Marketing for Marathon Pharmaceuticals, leading Marathon's marketing efforts for the commercialization of Emflaza. From January 2016 to August 2016, Mr. Del Carmen served as Vice President of Sales at Insys Therapeutics. From August 2011 until January 2016, Mr. Del Carmen was employed by Lundbeck Inc., where for the last two years of his tenure at Lundbeck he was the Movement Disorder National Sales Director. Prior to joining Lundbeck, Mr. Del Carmen spent 16 years at Abbott Laboratories in various sales and marketing leadership roles, with increasing responsibility. Mr. Del Carmen holds a Bachelor of Arts degree in Economics from the University of Dayton and an Executive MBA Degree from the University of Wisconsin.
- Preethi Sundaram
Preethi Sundaram于2021年7月加入我们，担任我们的首席产品开发官。Sundaram博士拥有超过20年的管理和指导团队的经验，为患者提供拯救生命的药物。在加入Catalyst之前，Sundaram博士自2005年以来一直在赛诺菲担任各种职务，包括从2005年至2010年担任全球临床研究总监，负责国际发展，全球项目负责人，从2010年至2017年担任多个治疗领域项目的全球负责人兼副总裁，负责医疗业务，从2017年到2020年，以及自2020年10月起担任赛诺菲普通药品业务部门医疗业务全球负责人兼副总裁。在最后一个职位上，Sundaram博士负责关键的全球医疗运营职能部门的领导，包括监督投资组合财务和交付战略里程碑，并负责领导赛诺菲通用药品业务部门所有治疗领域的多个投资组合管理职能部门。在加入赛诺菲之前，Sundaram博士于2005年担任项目负责人，雅培公司免疫科学发展中心；2003年至2005年，Sundaram博士担任Covance的医学作家和项目负责人；2001年至2003年，Sundaram博士担任Neurovision&Medical Services的临床主任；1997年至2001年，Sundaram博士担任研究生助教1995年至1997年间，Sundaram博士在印度金奈的Sankara Nethralaya眼科医院担任临床教员。Sundaram博士拥有印度马德拉斯大学心理学文学学士学位，印度精英视光和BITS学院的视光理学学士学位，英国安格利亚罗斯金大学的视光哲学博士学位，以及伦敦商学院的高管商务硕士学位。
Preethi Sundaram,has been Catalyst Pharmaceuticals, Inc. Chief Strategy Officer since January 1, 2022. Previously, since July 2021, Dr. Sundaram served as Catalyst Pharmaceuticals, Inc. Chief Product Development Officer. Dr. Sundaram has more than 20 years' experience managing and mentoring teams delivering lifesaving medicines to patients. Prior to her employment with Catalyst, since 2005, Dr. Sundaram was employed in various positions with Sanofi, including as Global Clinical Research Director, International Development from 2005-2010, Global Project Head, Multiple Therapeutic Area Programs from 2010 to 2017, Global Head and VP, Medical Operations, Primary Care Business Unit from 2017 to 2020, and since October 2020, as Sanofi's Global Head and VP, Medical Operations, General Medicines Business Unit. In that last position, Dr. Sundaram was accountable for leadership of critical global medical operational functions, including the oversight of portfolio financials and delivery of strategic milestones, as well as being responsible for the leadership of multiple portfolio management functions across all therapeutic areas in Sanofi's Medicines Business Unit. Prior to joining Sanofi, in 2005 Dr. Sundaram served as a Project Lead, Immunoscience Development Center for Abbott Laboratories; between 2003 to 2005, Dr. Sundaram served as a medical writer and project lead at Covance; between 2001 to 2003, Dr. Sundaram served as a Clinical Director with Neurovision & Medical Services; between 1997 to 2001, Dr. Sundaram was a Graduate Teaching Assistant and Clinical Supervisor at West Norwich Hospital in Cambridge, UK; and between 1995 to 1997, Dr. Sundaram was on the clinical faculty at the Sankara Nethralaya Eye Hospital in Chennai, India. Dr. Sundaram holds a Bachelor of Arts in Psychology from the University of Madras (India), a Bachelor of Science in Optometry from the Elite School of Optometry & Bits (India), a Doctor of Philosophy in Optometry from Anglia Ruskin University (United Kingdom), and an Executive Business Masters from the London Business School.- Preethi Sundaram于2021年7月加入我们，担任我们的首席产品开发官。Sundaram博士拥有超过20年的管理和指导团队的经验，为患者提供拯救生命的药物。在加入Catalyst之前，Sundaram博士自2005年以来一直在赛诺菲担任各种职务，包括从2005年至2010年担任全球临床研究总监，负责国际发展，全球项目负责人，从2010年至2017年担任多个治疗领域项目的全球负责人兼副总裁，负责医疗业务，从2017年到2020年，以及自2020年10月起担任赛诺菲普通药品业务部门医疗业务全球负责人兼副总裁。在最后一个职位上，Sundaram博士负责关键的全球医疗运营职能部门的领导，包括监督投资组合财务和交付战略里程碑，并负责领导赛诺菲通用药品业务部门所有治疗领域的多个投资组合管理职能部门。在加入赛诺菲之前，Sundaram博士于2005年担任项目负责人，雅培公司免疫科学发展中心；2003年至2005年，Sundaram博士担任Covance的医学作家和项目负责人；2001年至2003年，Sundaram博士担任Neurovision&Medical Services的临床主任；1997年至2001年，Sundaram博士担任研究生助教1995年至1997年间，Sundaram博士在印度金奈的Sankara Nethralaya眼科医院担任临床教员。Sundaram博士拥有印度马德拉斯大学心理学文学学士学位，印度精英视光和BITS学院的视光理学学士学位，英国安格利亚罗斯金大学的视光哲学博士学位，以及伦敦商学院的高管商务硕士学位。
- Preethi Sundaram,has been Catalyst Pharmaceuticals, Inc. Chief Strategy Officer since January 1, 2022. Previously, since July 2021, Dr. Sundaram served as Catalyst Pharmaceuticals, Inc. Chief Product Development Officer. Dr. Sundaram has more than 20 years' experience managing and mentoring teams delivering lifesaving medicines to patients. Prior to her employment with Catalyst, since 2005, Dr. Sundaram was employed in various positions with Sanofi, including as Global Clinical Research Director, International Development from 2005-2010, Global Project Head, Multiple Therapeutic Area Programs from 2010 to 2017, Global Head and VP, Medical Operations, Primary Care Business Unit from 2017 to 2020, and since October 2020, as Sanofi's Global Head and VP, Medical Operations, General Medicines Business Unit. In that last position, Dr. Sundaram was accountable for leadership of critical global medical operational functions, including the oversight of portfolio financials and delivery of strategic milestones, as well as being responsible for the leadership of multiple portfolio management functions across all therapeutic areas in Sanofi's Medicines Business Unit. Prior to joining Sanofi, in 2005 Dr. Sundaram served as a Project Lead, Immunoscience Development Center for Abbott Laboratories; between 2003 to 2005, Dr. Sundaram served as a medical writer and project lead at Covance; between 2001 to 2003, Dr. Sundaram served as a Clinical Director with Neurovision & Medical Services; between 1997 to 2001, Dr. Sundaram was a Graduate Teaching Assistant and Clinical Supervisor at West Norwich Hospital in Cambridge, UK; and between 1995 to 1997, Dr. Sundaram was on the clinical faculty at the Sankara Nethralaya Eye Hospital in Chennai, India. Dr. Sundaram holds a Bachelor of Arts in Psychology from the University of Madras (India), a Bachelor of Science in Optometry from the Elite School of Optometry & Bits (India), a Doctor of Philosophy in Optometry from Anglia Ruskin University (United Kingdom), and an Executive Business Masters from the London Business School.
- Patrick J. McEnany
Patrick J. McEnany，是Catalyst Pharmaceuticals, Inc.的联合创始人，目前担任Catalyst Pharmaceuticals, Inc.的董事。董事长、总裁兼首席执行官（“首席执行官”）。他曾担任Catalyst Pharmaceuticals, Inc.；自2002年1月Catalyst Pharmaceuticals, Inc.成立以来担任首席执行官和董事。他于2006年3月成为董事长兼总裁。从1999年到2002年，他是制药行业的顾问。从1991年到1997年，他担任Royce Laboratories, Inc.（仿制药制造商）的董事长兼首席执行官。从1997年到1998年，在Royce与Watson Pharmaceuticals, Inc.合并后，他担任全资子公司Royce Laboratories的总裁和Watson Pharmaceuticals, Inc.的企业发展副总裁。从1993年到1997年，他还担任the National Association of Pharmaceutical Manufacturers的副主席兼董事。他目前担任Jackson Health Foundation的名誉董事会成员和the Humane Society of Greater Miami的董事会成员。
Patrick J. McEnany,is a co-founder of Catalyst Pharmaceuticals, Inc. and currently serves as Catalyst Pharmaceuticals, Inc. Chairman, President and Chief Executive Officer ("CEO"). Mr. McEnany has been Catalyst Pharmaceuticals, Inc. CEO and a director since Catalyst Pharmaceuticals, Inc. formation in January 2002. He became Chairman and President in March 2006. From 1999 to 2002, Mr. McEnany was a consultant to the pharmaceutical industry. From 1991 to 1997, Mr. McEnany was Chairman and CEO of Royce Laboratories, Inc., a generic pharmaceutical manufacturer. From 1997 to 1998, after the merger of Royce into Watson Pharmaceuticals, Inc., Mr. McEnany served as president of the wholly-owned Royce Laboratories subsidiary and vice president of corporate development for Watson Pharmaceuticals, Inc. From 1993 to 1997, he also served as vice chairman and a director of the National Association of Pharmaceutical Manufacturers. He currently serves on an emeritus board of directors of the Jackson Health Foundation and on the board of directors of the Humane Society of Greater Miami.- Patrick J. McEnany，是Catalyst Pharmaceuticals, Inc.的联合创始人，目前担任Catalyst Pharmaceuticals, Inc.的董事。董事长、总裁兼首席执行官（“首席执行官”）。他曾担任Catalyst Pharmaceuticals, Inc.；自2002年1月Catalyst Pharmaceuticals, Inc.成立以来担任首席执行官和董事。他于2006年3月成为董事长兼总裁。从1999年到2002年，他是制药行业的顾问。从1991年到1997年，他担任Royce Laboratories, Inc.（仿制药制造商）的董事长兼首席执行官。从1997年到1998年，在Royce与Watson Pharmaceuticals, Inc.合并后，他担任全资子公司Royce Laboratories的总裁和Watson Pharmaceuticals, Inc.的企业发展副总裁。从1993年到1997年，他还担任the National Association of Pharmaceutical Manufacturers的副主席兼董事。他目前担任Jackson Health Foundation的名誉董事会成员和the Humane Society of Greater Miami的董事会成员。
- Patrick J. McEnany,is a co-founder of Catalyst Pharmaceuticals, Inc. and currently serves as Catalyst Pharmaceuticals, Inc. Chairman, President and Chief Executive Officer ("CEO"). Mr. McEnany has been Catalyst Pharmaceuticals, Inc. CEO and a director since Catalyst Pharmaceuticals, Inc. formation in January 2002. He became Chairman and President in March 2006. From 1999 to 2002, Mr. McEnany was a consultant to the pharmaceutical industry. From 1991 to 1997, Mr. McEnany was Chairman and CEO of Royce Laboratories, Inc., a generic pharmaceutical manufacturer. From 1997 to 1998, after the merger of Royce into Watson Pharmaceuticals, Inc., Mr. McEnany served as president of the wholly-owned Royce Laboratories subsidiary and vice president of corporate development for Watson Pharmaceuticals, Inc. From 1993 to 1997, he also served as vice chairman and a director of the National Association of Pharmaceutical Manufacturers. He currently serves on an emeritus board of directors of the Jackson Health Foundation and on the board of directors of the Humane Society of Greater Miami.
- Steven R. Miller
Steven R. Miller，自2011年1月起担任Catalyst Pharmaceuticals, Inc.的首席运营官。自2009年10月起担任首席科学官。此前，从2007年4月开始，Miller博士在Catalyst Pharmaceuticals, Inc.任职。药物开发和项目管理副总裁。Miller博士在医疗保健行业工作了30多年。在加入Catalyst Pharmaceuticals, Inc.之前，Miller博士在Watson Laboratories （Watson Pharmaceuticals, Inc.的子公司）的各个部门工作了15年，最近担任研发运营执行董事。在此职位上，Miller博士管理着一个75人的团队，负责所有研发产品的临床试验测试，包括方法评估、稳定性测试、研发中试工厂的运营、药物申请CMC部分的组装，以及其他职责。在担任此职位之前，他是。Miller是Watson Laboratories的技术转移主管，Royce Laboratories的研究和产品开发副总裁，该公司随后被Watson Laboratories收购。在加入Royce Laboratories之前，Miller博士是Dade Behring的组长和高级科学家。在此之前，他曾担任美国食品和药物管理局的分析化学家。他持有the University of Maryland的化学学士学位和the University of Miami的博士学位。
Steven R. Miller,has served as Chief Operating Officer since January 2011 and as Catalyst Pharmaceuticals, Inc. Chief Scientific Officer since October 2009. Previously, commencing in April 2007, Dr. Miller was Catalyst Pharmaceuticals, Inc. Vice President of Pharmaceutical Development and Project Management. Dr. Miller has worked in the healthcare industry for over 30 years. Prior to joining Catalyst Pharmaceuticals, Inc. , Dr. Miller spent 15 years with various divisions of Watson Laboratories, a subsidiary of Watson Pharmaceuticals, Inc., most recently as Executive Director of R&D Operations. In this capacity, Dr. Miller managed a team of 75 in the testing of all R&D products for clinical trials, including method valuation, stability testing, operation of the R&D pilot plant, and assembly of the CMC section of drug applications, in addition to other responsibilities. Prior to holding this position,Dr. Miller was Director of Technology Transfer for Watson Laboratories, and Vice President of Research and Product Development for Royce Laboratories, which was subsequently acquired by Watson Laboratories. Prior to joining Royce Laboratories, Dr. Miller was Group Leader and Senior Scientist at Dade Behring. Prior to that, he served as an Analytical Chemist at the U.S. Food & Drug Administration. Dr. Miller received his Bachelor of Science Degree in Chemistry from the University of Maryland and his Ph.D. from the University of Miami.- Steven R. Miller，自2011年1月起担任Catalyst Pharmaceuticals, Inc.的首席运营官。自2009年10月起担任首席科学官。此前，从2007年4月开始，Miller博士在Catalyst Pharmaceuticals, Inc.任职。药物开发和项目管理副总裁。Miller博士在医疗保健行业工作了30多年。在加入Catalyst Pharmaceuticals, Inc.之前，Miller博士在Watson Laboratories （Watson Pharmaceuticals, Inc.的子公司）的各个部门工作了15年，最近担任研发运营执行董事。在此职位上，Miller博士管理着一个75人的团队，负责所有研发产品的临床试验测试，包括方法评估、稳定性测试、研发中试工厂的运营、药物申请CMC部分的组装，以及其他职责。在担任此职位之前，他是。Miller是Watson Laboratories的技术转移主管，Royce Laboratories的研究和产品开发副总裁，该公司随后被Watson Laboratories收购。在加入Royce Laboratories之前，Miller博士是Dade Behring的组长和高级科学家。在此之前，他曾担任美国食品和药物管理局的分析化学家。他持有the University of Maryland的化学学士学位和the University of Miami的博士学位。
- Steven R. Miller,has served as Chief Operating Officer since January 2011 and as Catalyst Pharmaceuticals, Inc. Chief Scientific Officer since October 2009. Previously, commencing in April 2007, Dr. Miller was Catalyst Pharmaceuticals, Inc. Vice President of Pharmaceutical Development and Project Management. Dr. Miller has worked in the healthcare industry for over 30 years. Prior to joining Catalyst Pharmaceuticals, Inc. , Dr. Miller spent 15 years with various divisions of Watson Laboratories, a subsidiary of Watson Pharmaceuticals, Inc., most recently as Executive Director of R&D Operations. In this capacity, Dr. Miller managed a team of 75 in the testing of all R&D products for clinical trials, including method valuation, stability testing, operation of the R&D pilot plant, and assembly of the CMC section of drug applications, in addition to other responsibilities. Prior to holding this position,Dr. Miller was Director of Technology Transfer for Watson Laboratories, and Vice President of Research and Product Development for Royce Laboratories, which was subsequently acquired by Watson Laboratories. Prior to joining Royce Laboratories, Dr. Miller was Group Leader and Senior Scientist at Dade Behring. Prior to that, he served as an Analytical Chemist at the U.S. Food & Drug Administration. Dr. Miller received his Bachelor of Science Degree in Chemistry from the University of Maryland and his Ph.D. from the University of Miami.
- Alicia Grande
Alicia Grande，曾担任Catalyst Pharmaceuticals, Inc.自2011年12月起担任Catalyst Pharmaceuticals, Inc.副总裁、财务主管兼首席财务官。自2007年1月起担任首席会计官。加入Catalyst之前，自2003年起，她受雇于The Hackett Group, Inc.（上市战略咨询、企业基准和最佳实践转型公司）。她曾担任The Hackett Group的各种职务，最近担任财务高级总监，并负责所有外部和SEC财务报告。她还曾担任The Hackett Group的Sarbanes-Oxley Act合规团队的负责人。在加入The Hackett Group之前，她受雇于公共会计部门，并在Arthur Andersen LLP开始了她的职业生涯。她持有Syracuse University的工商管理学士学位，主修会计和金融，以及Florida International University的会计硕士学位。
Alicia Grande,has served as Catalyst Pharmaceuticals, Inc. Vice President, Treasurer and Chief Financial Officer since December 2011 and as Catalyst Pharmaceuticals, Inc. Chief Accounting Officer since January 2007. Prior to joining Catalyst, since 2003 Ms. Grande was employed by The Hackett Group, Inc., a publicly traded strategic consultancy, enterprise benchmarking and best practices transformation company. Ms. Grande served in various capacities with The Hackett Group, most recently as Senior Director of Finance, and was responsible for all external and SEC financial reporting. Ms. Grande also served as head of The Hackett Group's Sarbanes-Oxley Act compliance team. Prior to joining The Hackett Group, Ms. Grande was employed in public accounting, and she began her career with Arthur Andersen LLP. Ms. Grande earned a Bachelor of Science degree in business administration, with majors in accounting and finance, from Syracuse University and a Master of Accounting degree from Florida International University.- Alicia Grande，曾担任Catalyst Pharmaceuticals, Inc.自2011年12月起担任Catalyst Pharmaceuticals, Inc.副总裁、财务主管兼首席财务官。自2007年1月起担任首席会计官。加入Catalyst之前，自2003年起，她受雇于The Hackett Group, Inc.（上市战略咨询、企业基准和最佳实践转型公司）。她曾担任The Hackett Group的各种职务，最近担任财务高级总监，并负责所有外部和SEC财务报告。她还曾担任The Hackett Group的Sarbanes-Oxley Act合规团队的负责人。在加入The Hackett Group之前，她受雇于公共会计部门，并在Arthur Andersen LLP开始了她的职业生涯。她持有Syracuse University的工商管理学士学位，主修会计和金融，以及Florida International University的会计硕士学位。
- Alicia Grande,has served as Catalyst Pharmaceuticals, Inc. Vice President, Treasurer and Chief Financial Officer since December 2011 and as Catalyst Pharmaceuticals, Inc. Chief Accounting Officer since January 2007. Prior to joining Catalyst, since 2003 Ms. Grande was employed by The Hackett Group, Inc., a publicly traded strategic consultancy, enterprise benchmarking and best practices transformation company. Ms. Grande served in various capacities with The Hackett Group, most recently as Senior Director of Finance, and was responsible for all external and SEC financial reporting. Ms. Grande also served as head of The Hackett Group's Sarbanes-Oxley Act compliance team. Prior to joining The Hackett Group, Ms. Grande was employed in public accounting, and she began her career with Arthur Andersen LLP. Ms. Grande earned a Bachelor of Science degree in business administration, with majors in accounting and finance, from Syracuse University and a Master of Accounting degree from Florida International University.